Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on April 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(9):681-682; doi:10.1093/jnci/djn104
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/9/681    most recent
djn104v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Armstrong, A. J.
Right arrow Articles by Eisenberger, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, A. J.
Right arrow Articles by Eisenberger, M.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens

Andrew J. Armstrong, Elizabeth L. Garrett-Mayer, Mario Eisenberger

Affiliations of authors: Duke University Comprehensive Cancer Center and the Duke Prostate Center, Duke University, Durham, NC (AJA); Hollings Cancer Center, Department of Biostatistics, Medical University of South Carolina, Charleston, SC (ELGM); Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD (ME)

Correspondence to: Andrew J. Armstrong, MD, ScM, Duke University Comprehensive Cancer Center and the Duke Prostate Center, Duke University, Durham, NC (e-mail: andrew.armstrong@duke.edu).

The first 10% of the full text of this article appears below.

We commend Thall et al. (1) for their report on a four-arm crossover randomized phase II study of complex multiagent chemotherapy regimens in men with castration-resistant prostate cancer. The sequentially randomized design proposed by Thall et al. (1) is an attractive method that may enhance our ability to select a potentially active new regimen that deserves further testing. Indeed, they show that . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

Response:Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens
Randall E. Millikan, Christopher J. Logothetis, and Peter F. Thall
J Natl Cancer Inst 2008 100: 682-683. [Extract] [Full Text] [PDF]